Workflow
ROIC to WACC ratio
icon
Search documents
Northern Trust Corporation's Financial Efficiency Compared to Peers
Financial Modeling Prep· 2026-01-24 17:00
Core Insights - Northern Trust Corporation is a significant player in the financial services sector, providing a variety of services such as asset servicing, fund administration, investment management, and banking solutions, with a global reach targeting corporations, institutions, and affluent individuals [1] Financial Efficiency Analysis - Northern Trust's Return on Invested Capital (ROIC) stands at 6.78%, while its Weighted Average Cost of Capital (WACC) is 19.12%, resulting in a ROIC to WACC ratio of 0.35, indicating that the company is not generating returns above its cost of capital [2] - In comparison, State Street Corporation has a ROIC of 63.17% and a WACC of 15.35%, leading to a ROIC to WACC ratio of 4.12, showcasing its superior efficiency in generating returns well above its cost of capital [3] - Comerica Incorporated reports a ROIC of 3.40% and a WACC of 12.35%, yielding a ROIC to WACC ratio of 0.28, similar to Northern Trust, indicating challenges in capital utilization [4] - M&T Bank Corporation and Zions Bancorporation have ROIC to WACC ratios of 0.60 and 0.26, respectively, with M&T Bank showing a more favorable balance compared to Northern Trust, while Zions faces similar efficiency challenges [5] - Marsh & McLennan Companies has a ROIC to WACC ratio of 1.84, demonstrating a strong ability to generate returns above its cost of capital, though not as high as State Street [5]
Vyome Holdings, Inc. (HIND) Capital Utilization Challenges
Financial Modeling Prep· 2025-11-22 17:00
Company Analysis - Vyome Holdings, Inc. (HIND) has a Return on Invested Capital (ROIC) of -369.22%, significantly below its Weighted Average Cost of Capital (WACC) of 4.13%, indicating poor capital utilization [1][6] - Digital Brands Group, Inc. (DBGI) has a less negative ROIC of -63.30% and a WACC of 38.33%, resulting in a ROIC to WACC ratio of -1.65, suggesting relatively better capital efficiency compared to Vyome [2][6] - Palisade Bio, Inc. (PALI) shows a negative ROIC of -309.15% against a WACC of 11.16%, leading to a ROIC to WACC ratio of -27.70, indicating struggles in generating returns [3][6] - Ensysce Biosciences, Inc. (ENSC) has an even more negative ROIC of -874.14% with a WACC of 41.64%, resulting in a ROIC to WACC ratio of -20.99, highlighting significant challenges in capital utilization [4][6] - Grom Social Enterprises, Inc. (GROM) and NeuroBo Pharmaceuticals, Inc. (NRBO) exhibit negative ROICs of -59.49% and -269.72%, respectively, with WACCs of 33.38% and 5.00%, indicating widespread issues of negative returns across the peer group [5][6] Industry Overview - The analysis indicates a trend of negative ROIC across multiple companies within the industry, suggesting potential industry-wide challenges in capital efficiency and return generation [2][5][6]
Clearside Biomedical's Financial Performance in the Biopharmaceutical Industry
Financial Modeling Prep· 2025-11-21 17:00
Core Insights - Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing therapies for eye diseases using its proprietary SCS Microinjector for drug delivery [1] - The company faces competition from other biopharmaceutical firms such as Cidara Therapeutics, Selecta Biosciences, vTv Therapeutics, and Corvus Pharmaceuticals [1] Financial Performance - Clearside Biomedical has a Return on Invested Capital (ROIC) of -177.13%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 17.35% [2] - The negative ROIC indicates that the company is not generating positive returns on its invested capital, with a ROIC to WACC ratio of -10.21 highlighting inefficiencies in capital utilization [2] Peer Comparison - Cidara Therapeutics has a ROIC of -46.99% and a WACC of 10.99%, resulting in a less severe ROIC to WACC ratio of -4.27 compared to Clearside [3] - Selecta Biosciences shows a positive ROIC of 6.80% and a WACC of 8.38%, leading to a positive ROIC to WACC ratio of 0.81, indicating better capital efficiency [4] - vTv Therapeutics and Corvus Pharmaceuticals have negative ROIC to WACC ratios of -19.61 and -7.99, respectively, indicating challenges in generating returns above their cost of capital [4]
Ondas Holdings Inc. (NASDAQ:ONDS) Financial Analysis
Financial Modeling Prep· 2025-09-17 00:00
Company Overview - Ondas Holdings Inc. focuses on providing wireless data solutions for mission-critical services and operates in a competitive landscape with peers like CuriosityStream Inc., LifeMD, Inc., Kubient, Inc., ClearPoint Neuro, Inc., and Porch Group, Inc. [1] Financial Metrics - Ondas Holdings Inc. has a Weighted Average Cost of Capital (WACC) of 11.85% and a Return on Invested Capital (ROIC) of -22.60%, resulting in a ROIC to WACC ratio of -1.91, indicating inefficient use of capital [2][6] - CuriosityStream Inc. has a WACC of 12.05% and a ROIC of -8.63%, leading to a ROIC to WACC ratio of -0.72, which is less severe than Ondas but still indicates inefficiency [3] - LifeMD, Inc. has a WACC of 10.79% and a ROIC of 26.57%, resulting in a positive ROIC to WACC ratio of 2.46, suggesting effective capital utilization [4][6] - Kubient, Inc. and ClearPoint Neuro, Inc. both have negative ROIC to WACC ratios of -7.83 and -5.21, respectively, indicating significant challenges in generating returns [5] - Porch Group, Inc. has a ROIC to WACC ratio of 0.34, showing modest positive returns and some level of capital efficiency, though not as strong as LifeMD [5][6]